Journal: Scientific Reports
Article Title: Combination of THU/ALK-5i exhibits profound anti-MASH activity through suppression of lipogenesis and fibrogenesis
doi: 10.1038/s41598-025-23626-3
Figure Lengend Snippet: EW-7197 attenuates hepatocellular fibrosis with lipid metabolism derangement in hepatocytes. Cellular morphology after treatment ( A ). BODIPY staining ( B ). α-SMA staining ( C ). Expression of p-Smad3 and the downstream proteins (Col1A, α-SMA, and CTGF) in the canonical pathway ( D ). Representative bar graphs of p-Smad3 and its downstream profibrotic proteins ( E , F ). Lipid droplet count/cell ( G ). Lipid droplet area/cell ( H ). Lipid droplet intensity/cell ( I ). Protein levels of lipogenic genes; Srebp-1c and Fasn ( J ). Representative bar graphs of the lipogenic genes ( K ). * p < 0.05, † p < 0.01 vs. CON group, ‡ p < 0.05, § p < 0.01 vs. TGF-β control group, ŧ p < 0.05 vs. TGF-β plus EW group. px; pixels, a.u.; arbitrary units. Values are presented as the means ± SEM.
Article Snippet: The following antibodies were used: α-smooth muscle actin (α-SMA; SC-32251), collagen type I (Col1A; SC-293182), connective tissue growth factor (CTGF; SC-101586), sterol regulatory element-binding protein-1c (Srebp-1c; #SC-13551), fatty acid synthase (Fasn; SC-55580), monocyte chemoattractant protein-1 (MCP-1; SC-28879), interleukin-1β (IL-1β; SC-12742), and β-actin (SC-47778), which purchased from Santa Cruz Biotechnology (CA, USA).
Techniques: Staining, Expressing, Control